BLINATUMOMAB BRIDGING THERAPY FOR EFFECTIVE MANAGEMENT OF MRD IN PRO-B ALL WITH CNS INVOLVEMENT: A CASE REPORT OF POST TRANSPLANT PATIENT AT 23 MONTHS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION
Objective: Pro-B ALL is an unusual and highly malignant form of ALL often presenting with CNS involvement. The involvement of the CNS makes the central objective of these treatments that is attaining and maintaining remission more challenging. This is a report of Pro-B ALL of a 52-year old female wh...
Saved in:
| Main Authors: | Ceren Dehri Bahşi, Birol Güvenç |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ponatinib/blinatumomab for relapsed Philadelphia chromosome-positive leukemia as a bridge to allogeneic transplantation
by: Yasutaka Sadaga, et al.
Published: (2025-12-01) -
Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial
by: SN Bondarenko, et al.
Published: (2019-03-01) -
Novel outpatient infusion model of blinatumomab: case studies of two patients
by: LI Guijun, et al.
Published: (2025-04-01) -
Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis
by: Huai-Peng Guo, et al.
Published: (2024-12-01) -
Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia
by: Weiling Yan, et al.
Published: (2025-08-01)